ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10 Top-line results expected H1 2022Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness LEIDEN, Netherlands...